Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Body Weight Reduction and Metabolic/Biochemical Parameters in Overweight or Obesity

8. juni 2026 oppdatert av: Medical University of Silesia

The Effect of Body Weight Reduction on Selected Metabolic and Biochemical Parameters in Individuals With Overweight or Obesity

This was a single-center prospective observational cohort study conducted in Poland in the context of routine metabolic outpatient care. The study assessed selected metabolic, biochemical, oxidative-stress, inflammatory, and body-composition parameters in individuals with overweight or obesity undergoing standard lifestyle-based body weight reduction management. Participants with BMI > 25 kg/m² were followed before and after body weight reduction, while individuals with normal body weight served as a comparison group. The weight reduction management included individualized dietary recommendations, physical-activity guidance, health education, regular follow-up visits, fasting blood sampling, and body-composition assessment. The aim of the study was to evaluate whether body weight reduction is associated with changes in metabolic and biochemical parameters, with particular attention to glucose and lipid metabolism, oxidative stress, inflammatory markers, adipokines, cytokines, and body-composition changes.

Studieoversikt

Detaljert beskrivelse

This was a single-center prospective observational cohort study conducted at the Medical University of Silesia in Katowice, Poland, and in a metabolic outpatient clinic in Miasteczko Śląskie, Poland. The study was designed to evaluate the effect of body weight reduction on selected metabolic, biochemical, oxidative-stress, inflammatory, and body-composition parameters in individuals with overweight or obesity.

The study was conducted in the context of routine metabolic outpatient care. Participants with overweight or obesity received standard lifestyle-based body weight reduction management, including individualized dietary recommendations, physical-activity guidance, health education, and regular follow-up visits. The investigators did not assign participants to an investigational medicinal product, medical device, dietary supplement, surgical procedure, pharmacological intervention, or experimental therapy. The study prospectively observed participants receiving routine lifestyle-based weight reduction management and assessed changes in clinical and laboratory parameters before and after body weight reduction.

The approved study protocol planned the inclusion of individuals with overweight or obesity and a normal-weight comparison group. Participants with BMI > 25 kg/m² were evaluated in relation to body weight reduction, while individuals with normal body weight served as a comparison group for selected baseline analyses. Patients with overweight or obesity were assessed by medical examination, dietary and clinical questionnaires, anthropometric measurements, body-composition analysis, and fasting blood sampling. Body-composition analysis included assessment of body weight, fat mass, fat-free mass, skeletal muscle mass, total body water, visceral fat, and related parameters. Blood samples were collected for biochemical analyses, including markers of glucose metabolism, lipid metabolism, oxidative stress, antioxidant status, inflammatory markers, adipokines, cytokines, chemokines, growth factors, and selected cardiovascular-risk parameters.

Participants with overweight or obesity were followed during standard body weight reduction management until clinically relevant weight reduction or achievement of optimal body weight. According to the original study documentation, assessments were planned before the start of weight reduction, after approximately 10% body weight reduction, and after approximately 20% body weight reduction or achievement of target body weight. Follow-up visits included body weight measurements, waist and hip circumference measurements, dietary counselling, education regarding caloric intake, and motivation to continue lifestyle modification.

The primary objective of the study was to assess whether body weight reduction in individuals with overweight or obesity is associated with changes in selected metabolic and biochemical parameters. Secondary objectives included evaluation of oxidative-stress and antioxidant-status parameters, glucose and lipid metabolism, inflammatory markers, adipokines, cytokines, and body-composition changes. The study also aimed to assess relationships between biochemical parameters and body-composition indices before and after body weight reduction.

The study was approved by the Bioethics Committee of the Medical University of Silesia in Katowice, Poland. All participants received information about the study and provided written informed consent before participation. This ClinicalTrials.gov record is submitted retrospectively to meet journal publication requirements and to provide transparent public information about the completed study.

Studietype

Observasjonsmessig

Registrering (Faktiske)

53

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Silesian Voivodeship
      • Miasteczko Śląskie, Silesian Voivodeship, Polen, 42-610
        • Eko-Prof-Med Medical Center, Metabolic Outpatient Clinic
      • Zabrze, Silesian Voivodeship, Polen, 41-808
        • Department of Biochemistry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Adults with overweight or obesity who received routine lifestyle-based body weight reduction management in a metabolic outpatient clinic in Miasteczko Śląskie, Poland, and who provided written informed consent for participation in the study.

Beskrivelse

Inclusion Criteria:

  • Adults aged 18-85 years
  • BMI > 25 kg/m²
  • Overweight or obesity diagnosed on the basis of medical examination and body-composition assessment
  • Participation in routine lifestyle-based body weight reduction management in a metabolic outpatient clinic
  • Written informed consent to participate in the study

Exclusion Criteria:

  • Lack of informed consent
  • Severe hepatic insufficiency
  • Severe renal insufficiency
  • Severe respiratory insufficiency
  • Severe circulatory insufficiency
  • Disturbances of consciousness
  • Treatment-resistant depression
  • Chronic alcohol abuse
  • Pregnancy
  • History of serious nervous system injury
  • Implanted cardiac pacemaker
  • Pharmacological treatment affecting glucose and/or lipid metabolism
  • Incomplete follow-up or incomplete laboratory data

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Individuals With Overweight or Obesity
Adults with BMI > 25 kg/m² who were receiving routine lifestyle-based body weight reduction management in a metabolic outpatient clinic. Participants were prospectively observed and assessed before and after body weight reduction. Assessments included clinical and dietary questionnaires, anthropometric measurements, body-composition analysis, fasting blood sampling, and biochemical, metabolic, oxidative-stress, inflammatory, adipokine, and cytokine measurements.
Standard lifestyle-based body weight reduction management received as part of routine metabolic outpatient care. It included individualized dietary recommendations, physical-activity guidance, health education, and regular follow-up visits. Participants were not assigned to this management as part of the study; the study prospectively observed patients receiving routine care and assessed metabolic, biochemical, inflammatory, oxidative-stress, adipokine, cytokine, and body-composition parameters before and after body weight reduction.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Body Weight
Tidsramme: Baseline and after body weight reduction, up to approximately 6 months
Change in body weight from baseline to follow-up after routine lifestyle-based body weight reduction management.
Baseline and after body weight reduction, up to approximately 6 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Body Fat Mass
Tidsramme: Baseline and after body weight reduction, up to approximately 6 months
Change in body fat mass assessed by bioelectrical impedance analysis and expressed in kilograms.
Baseline and after body weight reduction, up to approximately 6 months
Change in Glucose concentration in mg/dl.
Tidsramme: Baseline and after body weight reduction, up to approximately 6 months
Changes in fasting glucose.
Baseline and after body weight reduction, up to approximately 6 months
Change in total-cholesterol concentration in mg/dl.
Tidsramme: Baseline and after body weight reduction, up to approximately 6 months
Changes in total cholesterol concentration.
Baseline and after body weight reduction, up to approximately 6 months
Change in malondialdehyde concentration in μmol/l.
Tidsramme: Baseline and after body weight reduction, up to approximately 6 months
Change in blood malondialdehyde concentration, assessed as a marker of lipid peroxidation and oxidative stress, from baseline to follow-up after body weight reduction.
Baseline and after body weight reduction, up to approximately 6 months
Change in serum IL-6 concentration in pg/ml.
Tidsramme: Baseline and after body weight reduction, up to approximately 6 months
Change in serum interleukin-6 (IL-6) concentration from baseline to follow-up after body weight reduction. IL-6 was measured in serum samples as a marker of systemic low-grade inflammation and expressed in pg/ml.
Baseline and after body weight reduction, up to approximately 6 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Sławomir Kasperczyk, Prof, Medical University of Silesia in Katowice

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

10. mai 2016

Primær fullføring (Faktiske)

30. september 2022

Studiet fullført (Faktiske)

30. september 2022

Datoer for studieregistrering

Først innsendt

2. juni 2026

Først innsendt som oppfylte QC-kriteriene

8. juni 2026

Først lagt ut (Faktiske)

12. juni 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. juni 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

8. juni 2026

Sist bekreftet

1. juni 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • KNW/0022/KB1/19/I/16
  • Secondary ID: KNW-1-016/N/7/2 (Annet stipend/finansieringsnummer: Medical University of Silesia)
  • Secondary ID: KNW-1/109/K/8/Z (Annen identifikator: Medical University of Silesia)
  • Secondary ID: KNW-1/171/K/9/O (Annen identifikator: Medical University of Silesia)
  • Secondary ID: PCN-1-049/K/0/O (Annen identifikator: Medical University of Silesia)
  • Secondary ID: PCN-1-018/K/1/O (Annen identifikator: Medical University of Silesia)
  • Secondary ID: PCN-1-132/K/2/O (Annen identifikator: Medical University of Silesia)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Individual participant data will not be made publicly available because of privacy and confidentiality restrictions, limitations of the original informed consent, and the retrospective registration of this completed study. De-identified aggregate data or non-identifiable datasets may be made available from the investigators upon reasonable request, subject to institutional approval and applicable data protection regulations.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere